~~<i id='FD8F330039'><strike id='FD8F330039'><tt id='FD8F330039'><pre id='FD8F330039'></pre></tt></strike></i>~~

Home» comprehensive» focus

focus

author：explore 2025-10-02 08:43:31 Page View：2171

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： U.K. not yet recommending Vertex's CRISPR therapy for sickle cell
Next article： Continuity nursing helped my family in our darkest PICU moments

leisure time

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Readout Newsletter: Bluebird, CVS, Contineum

JustinSullivan/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetour

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

U.K. researchers warn about biases in medical devices, algorithms

Pulseoximeters,whichtrackbloodoxygenlevels,canoverestimatesuchlevelsinpatientswithdarkerskin,potenti